Jean-Louis Saillot
VP Compound Dev., Proj. Leadership, Reg. Affairs, Med. Writing, Biometrics, & Clin Pharmacology at Receptos A Whollyowned Subsidiary Of Celgene
Jean-Louis Saillot's Professional Contact Details
Email (Verified)
****@receptos.com
Location
New York, New York, US
Company
Receptos A Whollyowned Subsidiary Of Celgene
Person Seniority
vp
Jean-Louis Saillot's Current Company Details
Receptos is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy...
Receptos is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of our development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Public Symbol
RCPT
Founded Year
2009
Organization Website
receptos.com
Organization Languages
English
Organization Revenue
5900
Current Technologies
outlook
office 365
php 5 3
google analytics
wordpress org
hyrell
ulcerative colitis
biopharmaceutical
multiple sclerosis
biotechnology
biopharma
health care
health
wellness & fitness
Jean-Louis Saillot's Work History and Education
Receptos, a wholly-owned subsidiary of Celgene
VP Compound Dev., Proj. Leadership, Reg. Affairs, Med. Writing, Biometrics, & Clin Pharmacology
2016 - Present
Colleagues at Receptos A Whollyowned Subsidiary Of Celgene
Prospect on LinkedIn
Find emails on Linkedln, Sales Navigator, AngelList, CrunchBase, Google etc.
Download
Extension
